US-ECP Inc. is a leading provider of External Counterpulsation (ECP) therapy, a non-invasive and low-risk treatment for coronary artery disease and other non-cardiac ischemic degenerative disorders. With a technologically advanced sixth generation device, US-ECP Inc. offers physicians and hospitals an effective and reliable alternative to surgical or chemical intervention, aiming to improve clinical and economic outcomes for patients.
Originally pioneered in the U.S. in the late 1960s, ECP therapy was further developed and widely used in Asia and Europe while U.S. physicians explored surgical procedures. Reintroduced in the 1990s, US-ECP Inc.'s Model US-ECP has been approved by the FDA to provide non-surgical treatment for various cardiovascular conditions, including stable and unstable angina, congestive heart failure, and acute myocardial infarction.
Generated from the website